Results 211 to 220 of about 159,720 (266)

IMMUNOPHARMACOLOGY OF RAPAMYCIN

Annual Review of Immunology, 1996
▪ Abstract  The potent immunosuppressive drugs FK506 and rapamycin interfere with signal transduction pathways required for T cell activation and growth. The distinct inhibitory effects of these drugs on the T cell activation program are mediated through the formation of pharmacologically active complexes with members of a family of intracellular ...
R T, Abraham, G J, Wiederrecht
openaire   +2 more sources

Solubilization of rapamycin

International Journal of Pharmaceutics, 2001
The solubilization of rapamycin, a poorly water soluble investigational immunosuppressive drug, by facilitated hydrotropy is presented. Partially water-miscible aromatic solutes (such as benzyl alcohol, benzoate, or benzoic acid) can be solubilized by water-miscible cosolvents, such as ethanol and propylene glycol.
P, Simamora, J M, Alvarez, S H, Yalkowsky   +2 more
openaire   +2 more sources

Blood distribution of rapamycin

Clinical Biochemistry, 1993
Rapamycin (RAPA) is a potent new immunosuppressive drug. Although blood concentration monitoring of RAPA is being performed in preclinical and clinical trials, little is known regarding the blood distribution of the drug. Such information would have an impact on the medium used for analysis of the drug.
R, Yatscoff, D, LeGatt, R, Keenan, P, Chackowsky   +3 more
openaire   +2 more sources

Rapamycin (sirolimus, rapamune)

Current Opinion in Nephrology and Hypertension, 1995
Rapamycin is a novel immunosuppressive agent that is undergoing clinical trials for use in allograft rejection therapy. This paper reviews its in-vitro biological properties, the current state of knowledge concerning its mechanism of action, and its therapeutic applications.
S N, Sehgal, J S, Camardo, J A, Scarola, B T, Maida   +3 more
openaire   +2 more sources

Mammalian target of rapamycin

Seminars in Oncology, 2004
Targeted molecular therapeutics are tailored toward the genetic abnormalities that cause tumor progression. Modulation of certain signaling pathways that are aberrant in cancer cells has the potential to provide an effective, nontoxic approach to therapy in a broad range of cancers. Agents targeting BCR-ABL (imatinib mesylate [formerly known as STI-571]
Funda, Meric-Bernstam, Gordon B, Mills
openaire   +2 more sources

Swinging the vote for rapamycin

Nature Reviews Cancer, 2002
Abstract Immunosuppressive drugs are commonly used to prevent immunological graft rejection in organ transplant recipients, but these have many serious side effects, including increasing the patient's risk for developing cancer. Cancer is, in fact, one of the main causes of death in organ transplant recipients.
openaire   +2 more sources

Structural mechanism of allosteric activation of TRPML1 by PI(3,5)P 2 and rapamycin

Proceedings of the National Academy of Sciences of the United States of America, 2022
Ninghai Gan, Yan Han, Youxing Jiang
exaly  

Rapamycin: Therapeutic range investigations

Clinical Biochemistry, 1993
R Yatscoff, N Kneteman, J Fryer
openaire   +1 more source

Rapamycin and Thrombosis

Angiology, 2012
openaire   +2 more sources

Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth

Cell Chemical Biology, 2022
Yaoyang Zhang, Yunxia Li, Yu Yan
exaly